Moolec Science Scales GLASO U.S. Platform With Record 2025 Campaign and Expansion Into Nutrition & Supplements Market

Rhea-AI Summary

Moolec Science (NASDAQ:MLEC) announced completion of its 2025 U.S. GLASO1 safflower campaign, marking its first large-scale deployment of a plant-engineered molecular farming platform.

Key outcomes: 1,100 acres cultivated, average yield ~2,200 lb/acre versus 1,400 lb/acre in 2024 (a 57.1% YoY increase), and acreage expanded by more than 100% versus prior cycles. The company says harvests exceeded internal forecasts and validated large-volume harvest management, traceability, and quality controls.

Moolec plans to enter the U.S. nutrition and supplements market and pursue high-concentration GLA softgel applications to access premium channels and recurring demand.

Positive

• 1,100 acres deployed for GLASO1 safflower
• Average yield ~2,200 lb/acre in 2025
• Yield improvement +57.1% YoY from 2024
• Acreage expansion +100%+ versus prior cycles
• Market entry into U.S. nutrition & supplements
• Planned high-concentration GLA softgel commercialization

Negative

• None.

Key Figures

Share price $0.4661 Pre-news price on publication date

Safflower acreage 2025 1,100 acres GLASO1 safflower production across the United States

2025 yield 2,200 lb/acre Average yield in 2025 GLASO1 safflower campaign

2024 yield 1,400 lb/acre Average yield in 2024 safflower campaign

Yield increase 57.1% Year-over-year increase from 2024 to 2025 campaign

Acreage expansion More than 100% Increase in acreage relative to previous cycles

Patent number US11/438,951 GLASO-related U.S. patent referenced in article

Patent number US13/025,345 GLASO-related U.S. patent referenced in article

Market Reality Check

$0.4356 Last Close

Volume Volume 106,673 is below the 20-day average of 131,385, suggesting no unusual trading ahead of this update. normal

Technical Shares at 0.4661 are trading well below the 200-day MA of 4.2 and 95.55% under the 52-week high of 10.47.

Peers on Argus

Sector peers showed mixed moves, with names like NXTC up 5.98% and CARM down 25.33%, indicating today’s Moolec news is more company-specific than part of a broad biotech move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 28	Nasdaq filing delay	Negative	-2.3%	Nasdaq letter over delayed Form 20-F and related listing compliance issues.
Nov 21	Bid-price noncompliance	Negative	-1.6%	Nasdaq notice on sub-<b>$1.00</b> bid price and appeal for compliance plan.
Sep 11	Regulatory & ops update	Positive	+11.3%	Argentina GLASO approval, doubled U.S. acreage, CFO appointment, Mycofood integration.
Jun 18	Patent milestone	Positive	+14.8%	Core U.S. patent for Piggy Sooy™ soybean expressing high animal protein levels.
Jun 17	Business combination	Positive	-3.6%	Closing of multi-party business combination expanding capabilities across food-tech and life sciences.

Pattern Detected

Stock generally reacts positively to operational and IP milestones, while listing and compliance headlines have coincided with mild declines.

Recent Company History

Over the last six months, Moolec has combined strategic transactions and technology milestones with listing challenges. A June 2025 business combination broadened its life sciences and food-tech footprint, followed by a key patent win for Piggy Sooy™ and regulatory approval for GLASO technology in Argentina, alongside expanded U.S. acreage and a new CFO. More recently, Nasdaq letters highlighted bid-price and filing issues. Today’s GLASO1 scale-up news builds directly on the prior acreage expansion and regulatory progress noted on Sep 11, 2025.

Market Pulse Summary

The stock moved -6.7% in the session following this news. A negative reaction despite operational progress would fit a divergence pattern seen after the June business combination, when shares fell even on strategically positive news. With the price at $0.4661 and 95.55% below the 52-week high of 10.47, sentiment has already been weak amid Nasdaq bid-price and filing concerns. The GLASO1 scaling update may be overshadowed by listing risk and broader biotech volatility rather than company operations alone.

Key Terms

molecular farming medical

"large-scale expansion of its plant-engineered molecular farming platform."

Molecular farming is the use of genetically engineered plants, animals, or microbes as low-cost biological factories to produce useful proteins, vaccines, enzymes or other molecules that would otherwise come from complex laboratory processes. Investors care because it can cut manufacturing costs and scale production quickly—potentially boosting profit margins—but carries risks from regulatory approval, intellectual property, and production variability that can affect a company’s value and timelines.

functional lipids medical

"plant-engineered functional lipids"

Functional lipids are fats and oil-based molecules that provide a specific health benefit beyond basic nutrition, such as improving heart health, reducing inflammation, or supporting brain function. Investors care because these ingredients often command higher prices, can drive demand for premium food, supplement, or pharmaceutical products, and may face regulatory scrutiny or patent opportunities—think of them as specialized ingredients that can boost a product’s value like a premium feature on a gadget.

softgel technical

"expand into softgel nutritional applications with a high-concentration GLA formulation"

A softgel is a sealed, gelatin-based capsule that contains a liquid or semi-liquid dose of medicine or a dietary supplement, designed to be smooth and easy to swallow. Investors care about softgels because the form affects how fast a product works, its stability, manufacturing costs and regulatory review — like how packaging affects shipping, shelf life and customer appeal — all of which influence sales, margins and approval risk.

metabolic health medical

"operate at the intersection of metabolic health, personalized nutrition, and elite fitness"

Metabolic health describes how well a person’s body turns food into energy and keeps blood sugar, cholesterol, blood pressure, weight and inflammation in healthy ranges. It matters to investors because poor metabolic health drives demand for drugs, medical devices, diagnostics and wellness services, raises healthcare costs and affects workforce productivity—think of it as the engine efficiency of a population that influences market size and future earnings.

personalized nutrition medical

"intersection of metabolic health, personalized nutrition, and elite fitness"

Personalized nutrition is the practice of tailoring dietary advice, supplements or meal plans to an individual’s unique biology, lifestyle and goals using data such as genetic information, blood markers, wearable activity or food preferences. For investors, it matters because it shifts nutrition from one-size-fits-all products to targeted services and recurring data-driven offerings, potentially creating higher-margin businesses, stronger customer retention and new regulatory or privacy considerations.

AI-generated analysis. Not financial advice.

WARWICK, UK / ACCESS Newswire / December 11, 2025 / Moolec Science Limited, a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC; "the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced the successful completion of its 2025 U.S. GLASO¹ safflower campaign, representing the Company's first successful large-scale expansion of its plant-engineered molecular farming platform.

The 2025 campaign marks a major operational milestone, demonstrating that Moolec can deliver consistent performance at significantly increased acreage, transitioning from prior development and smaller-scale campaigns into successful large-scale agricultural execution.

2025 GLASO¹ Campaign Highlights

• 1,100 acres dedicated for safflower production across the United States

• Average yield of approximately 2,200 lb/acre, up from 1,400 lb/acre in 2024, representing a 57.1% year-over-year increase

• Harvest performance materially exceeded internal forecasts, reinforcing confidence in agronomic optimization and operational execution

Large-Scale Validation Across the Value Chain

With acreage expanded by more than 100% relative to previous cycles, the 2025 campaign provided the first demonstration that GLASO¹ can operate successfully at commercial scale, encompassing expanded field deployment and large-volume harvest management.

These results confirm Moolec's ability to translate its plant-engineered molecular farming platform from controlled deployments into large-scale agricultural operations, using existing farming infrastructure while maintaining traceability, quality, and cost discipline.

High-Growth Commercial Opportunity in Nutrition & Supplements

Moolec's planned entry into the nutrition and supplements market is supported by early demand from leading wellness and performance brands in the United States. These organizations operate at the intersection of metabolic health, personalized nutrition, and elite fitness, sectors characterized by strong growth, premium pricing, and stringent purity requirements.

Interest from these companies, each serving large, engaged consumer communities, provides Moolec with:

• Immediate access to high-value, recurring demand pools

• A market that prioritizes clean-label, traceable, plant-engineered functional lipids

• A commercial environment where high-concentration GLA offers differentiated formulation advantages

This early market pull positions GLASO¹ to enter one of the most dynamic segments of the nutrition industry.

Planned Expansion Into High-Concentration GLA Softgel Applications

Building on the success of the 2025 campaign, Moolec intends to expand into softgel nutritional applications with a high-concentration GLA formulation derived from its engineered safflower platform.

This planned expansion is expected to:

• Unlock higher value-added commercialization pathways

• Provide access to established global softgel distribution channels

• Differentiate GLASO¹ through concentration, purity, and plant-engineered origin

Execution-Led Growth Strategy

"The 2025 campaign represents a defining moment for GLASO¹," said Alejandro Antalich, CEO at Moolec Science. "Scaling acreage by more than 100% while strengthening performance shows the maturity of our plant-engineered platform. The interest we are receiving from influential wellness and performance brands signals a broader shift toward scientifically engineered functional lipids. With this year's success, GLASO¹ is equipped to move into higher-value formats such as concentrated softgels, unlocking a new phase of growth."

Focus on Fundamentals

Moolec continues to prioritize:

• Scaling validated platforms with discipline

• Capital-efficient growth aligned with demonstrated performance

• Transparent, execution-driven communication with shareholders

The Company views the 2025 GLASO¹ campaign as a foundational step toward repeatable commercial-scale production and accelerated entry into high-value nutritional markets.

¹ Pat. US11/438,951 and US13/025,345

About Moolec Science SA

Moolec Science is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating sustainable and commercially viable ingredients. The Company's diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than 118 granted and pending patents across multiple technology platforms. With operations spanning the United States, Europe and South America, Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq under the ticker "MLEC." For more information, please visit www.moolecscience.com and ir.moolecscience.com.

Forward Looking Statements

This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Moolec Science's Contacts:

Investor Relations inquiries: ir@moolecscience.com

SOURCE: Moolec Science

View the original press release on ACCESS Newswire

FAQ

What were Moolec Science's 2025 GLASO1 campaign results for MLEC on December 11, 2025?

The 2025 U.S. campaign used 1,100 acres with average yield ~2,200 lb/acre, a 57.1% increase versus 2024.

How much did GLASO1 acreage increase for MLEC in 2025?

Acreage expanded by more than 100% relative to previous cycles, enabling large-scale validation.

What commercial markets is MLEC targeting after the 2025 campaign?

Moolec plans entry into the U.S. nutrition and supplements market, targeting premium softgel channels.

What product format is Moolec planning for GLASO1 commercialization (MLEC)?

The company intends to develop a high-concentration GLA softgel formulation derived from engineered safflower.

Why do investors view the 2025 GLASO1 campaign as significant for MLEC?

It demonstrates scalable agricultural execution with higher yields, large-volume harvest management, and commercial channel access.

Did Moolec report that the 2025 harvest met internal expectations for MLEC?

Yes; harvest performance materially exceeded internal forecasts, reinforcing agronomic and operational confidence.